Switch to:
Onyx Pharmaceuticals, Inc. (NAS:ONXX)
Research and Development
$362.3 Mil (TTM As of Jun. 2013)

This is the expense the company spent on research and development. Onyx Pharmaceuticals, Inc.'s research and development for the three months ended in Jun. 2013 was $102.8 Mil. Its research and development for the trailing twelve months (TTM) ended in Jun. 2013 was $362.3 Mil.


Definition

This is the expense the company spent on research and development.

Onyx Pharmaceuticals, Inc. Research & Development for the trailing twelve months (TTM) ended in Jun. 2013 was 85.667 (Sep. 2012 ) + 82.573 (Dec. 2012 ) + 91.302 (Mar. 2013 ) + 102.761 (Jun. 2013 ) = $362.3 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Onyx Pharmaceuticals, Inc. Annual Data

Dec03Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12
Research & Development 33.635.863.131.083.3123.7128.5185.7268.1325.3

Onyx Pharmaceuticals, Inc. Quarterly Data

Mar11Jun11Sep11Dec11Mar12Jun12Sep12Dec12Mar13Jun13
Research & Development 62.563.058.584.080.776.485.782.691.3102.8
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide